Assessment of clinical outcomes in acute stroke trials

Stroke

Volumn 29, Issue 5, 1998, Pages 986-991

  Roberts, Lucy ^a   Counsell, Carl ^a,b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b AUSTIN HEALTH   (Australia)

Author keywords

Clinical trials; Outcome assessment; Stroke, acute

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM ANTAGONIST; CORTICOSTEROID; FIBRINOLYTIC AGENT;

ARTICLE; CLINICAL TRIAL; DEATH; DISABILITY; HEMODILUTION; HUMAN; MEASUREMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; STROKE; TREATMENT OUTCOME;

EID: 0031971819     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.5.986     Document Type: Article

References (39)

1. Frater A, Costain D. Any better? Outcome measures in medical audit. BMJ. 1992;304:519-520.
2. Spence JD, Donner A. Problems in design of stroke treatment trials. Stroke. 1982;13:94-99.
3. Harrison MJG, Ross Russell RW. Medical treatment. In: Harrison M, Dyken M, eds. Cerebral Vascular Disease. London, England: Butterworth; 1983:254-283.
4. International Classification of Impairments, Disabilities, and Handicaps. Geneva, Switzerland: World Health Organization; 1980.
5. Wade DT. Measurement in Neurological Rehabilitation. Oxford, England: Oxford University Press, Inc; 1992.
6. Ebrahim S. Clinical and public health perspectives and applications of health-related quality of life measurement. Soc Sci Med. 1995;41: 1383-1394.
7. Leplege A, Hunt S. The problem of quality of life in medicine. JAMA. 1997;278:47-50.
8. De Haan R, Horn J, Limburg M, Van Der Meulen J, Bossuyt P. A comparison of five stroke scales with measures of disability, handicap, and quality of life. Stroke. 1993;24:1178-1181.
9. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ. 1997;314: 1580-1583.
10. Orgogozo JM. The concepts of impairment, disability and handicap. Cerebrovasc Dis. 1994;4(suppl 2):2-6.
11. Dennis M, Wellwood I, McGregor K, Dent J, Forbes J. What are the major components of the cost of caring for stroke patients in hospital in the UK? Cerebrovasc Dis. 1995;5:243. Abstract.
12. van Gijn J. Measurement of outcome in stroke prevention trials. Cerebrovasc Dis. 1992;2(suppl. 1):23-34.
13. Warlow CP, Van Gijn J, Sandercock P, Candelise L, Langhorne P, eds. The Stroke Module of The Cochrane Database of Systematic Reviews. Available in: The Cochrane Library (database on disk and CD-ROM). The Cochrane Collaboration; issue 4. Oxford, England: Update Software; 1997. Updated quarterly.
14. De Haan R, Limburg M, Bossuyt P, Van Der Meulen J, Aaronson N. The clinical meaning of Rankin 'handicap' grades after stroke. Stroke. 1995; 26:2027-2030.
15. Roden-Jullig A, Britton M, Gustafsson C, Fugl-Meyer A. Validation of four scales for the acute stage of stroke. J Intern Med. 1994;236:125-136.
16. Hantson L, De Keyser J. Neurological scales in the assessment of cerebral infarction. Cerebrovasc Dis. 1994;4(suppl 2):7-14.
17. D'Olhaberriague L, Litvan I, Mitsias P, Mansbach HH. A reappraisal of reliability and validity studies in stroke. Stroke. 1996;27:2331-2336.
18. Lindmark B, Hamrin E. Evaluation of functional capacity after stroke as a basis for active intervention: presentation of a modified chart for motor capacity assessment and its reliability. Scand J Rehabil Med. 1988;20: 103-109.
19. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale: extension to non-neurologists in the context of a clinical trial. Stroke. 1997;28:307-310.
20. Turnhill JE, Pozen TJ, Kennedy FB. A neurologic grading system for acute stroke. Am Heart J. 1969;78:53-57.
21. Albizzati MG, Candelise L, Capitani E, Colombo A, Spinnler H. Association of glycerol to dexamethasone in treatment of stroke patients. Acta Neurol Scand. 1979;60:77-84.
22. Dove HG, Schneider KC, Wallace JD. Evaluating and predicting outcome of acute cerebral vascular accidents. Stroke. 1984;15:858-864.
23. Kartin P, Povse M, Skondia V. Clinical study of piracetam in patients with subacute cerebrovascular accidents. Acta Therapeutica. 1979;5: 235-243.
24. Ciufetti G, Aisa G, Mercuri M, Lombardini R, Paltricca R, Neri C, Senin U. Effects of ticlopidine on the neurologic outcome and the hemorrheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology. 1990;41:505-511.
25. Oxbury JM, Greenhall RC, Grainger KM. Predicting the outcome of stroke: acute stage after cerebral infarction. BMJ. 1975;3:125-127.
26. Patten BM, Mendell J, Bruun B, Curtin W, Carter S. Double blind study of the effects of dexamethasone on acute stroke. Neurology. 1972;22: 377-383.
27. Maas AIR, Braakman R, Schomen HJA, Minderhoud JM, van Zomer AH. Agreement between physicians of assessment of outcome following severe head injury. J Neurosurg. 1983;58:321-325.
28. Hamrin E, Wohlin A. I. Evaluation of the functional capacity of stroke patients through an activities index. Scand J Rehabil Med. 1982;14: 93-100.
29. Dennis M, Wellwood I, Warlow C. Are simple questions a valid measure of outcome after stroke? Cerebrovasc Dis. 1997;7:22-27.
30. Dennis M, Wellwood I, O'Rourke S, Machale S, Warlow C. How reliable are simple questions in assessing outcome after stroke? Cerebrovasc Dis. 1997;7:19-21.
31. Gompertz P, Pound P, Ebrahim S. The reliability of stroke outcome measures. Clin Rehabil. 1993;7:290-296.
32. Mulley G, Wilcox RG, Mitchell JRA. Dexamethasone in acute stroke. BMJ. 1978;2:994-996.
33. Hurwitz LJ, Adams GF. Rehabilitation of hemiplegia: indices of assessment and prognosis. BMJ. 1972;1:94-98.
34. Martin JF, Hamdy N, Nicholl J, Lewtas N, Bergvall U, Owen P, Syder D, Holroyd M. Double-blind controlled trial of prostacyclin in cerebral infarction. Stroke. 1985;16:386-390.
35. van Gijn J. Panel discussion. Cerebrovasc Dis. 1995;5(suppl 1):31-33.
36. Anonymous. Blinded by science. Lancet. I994;343:553-554.
37. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology. 1994;44: 16-20.
38. Schulz KF, Grimes DA, Altman DG, Hayes RJ. Blinding and exclusions after allocation in randomized controlled trials: survey of published parallel group trials in obstetrics and gynaecology. BMJ. 1996;312: 742-744.
39. Moher D, Fortin P, Jadad AR, Juni P, Klassen T, Le Lorier J, Liberati A, Linde K, Penna A. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet. 1996;347:363-366.